This HTML5 document contains 73 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00629/identifier/wikipedia/
n6http://linked.opendata.cz/resource/drugbank/drug/DB00629/identifier/pharmgkb/
foafhttp://xmlns.com/foaf/0.1/
n7http://linked.opendata.cz/resource/drugbank/company/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00629/identifier/kegg-compound/
n16http://linked.opendata.cz/resource/drugbank/drug/DB00629/identifier/pubchem-compound/
n14http://linked.opendata.cz/resource/drugbank/drug/DB00629/identifier/pubchem-substance/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00629/identifier/kegg-drug/
n11http://bio2rdf.org/drugbank:
n20http://linked.opendata.cz/resource/drugbank/drug/DB00629/identifier/drugbank/
admshttp://www.w3.org/ns/adms#
n10http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n21http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n15http://www.drugs.com/cdi/
n4http://linked.opendata.cz/resource/drugbank/property/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00629/identifier/chemspider/
n13http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB00629
rdf:type
n3:Drug
n3:description
An alpha-2 selective adrenergic agonist used as an antihypertensive agent. [PubChem]
n3:group
approved
n3:halfLife
6 hours.
n3:indication
For management of High blood pressure
n3:manufacturer
n7:271B5B85-363D-11E5-9242-09173F13E4C5 n7:271B5B86-363D-11E5-9242-09173F13E4C5 n7:271B5B83-363D-11E5-9242-09173F13E4C5 n7:271B5B84-363D-11E5-9242-09173F13E4C5 n7:271B5B82-363D-11E5-9242-09173F13E4C5
owl:sameAs
n10:DB00629 n11:DB00629
dcterms:title
Guanabenz
adms:identifier
n6:PA164774903 n14:46505200 n16:5702063 n17:C07034 n18:D04375 n19:3397 n20:DB00629 n22:Guanabenz
n3:mechanismOfAction
Guanabenz's antihypertensive effect is thought to be due to central alpha-adrenergic stimulation, which results in a decreased sympathetic outflow to the heart, kidneys, and peripheral vasculature in addition to a decreased systolic and diastolic blood pressure and a slight slowing of pulse rate. Chronic administration of guanabenz also causes a decrease in peripheral vascular resistance.
n3:packager
n7:271B5B7E-363D-11E5-9242-09173F13E4C5 n7:271B5B81-363D-11E5-9242-09173F13E4C5 n7:271B5B7F-363D-11E5-9242-09173F13E4C5 n7:271B5B80-363D-11E5-9242-09173F13E4C5
n3:synonym
Wytensin SID26751943 Guanabenz Guanabenzum SID26665151 WY-8678 Guanabenzo
n3:toxicity
Excessive contraction of the pupils, irritability, low blood pressure, sleepiness, slow heartbeat, sluggishness
n3:proteinBinding
90%
n3:salt
n3:synthesisReference
British Patent 1,019,120.
foaf:page
n13:gua1612.shtml n15:guanabenz.html
n3:IUPAC-Name
n4:271B5B8D-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B5B93-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B5B92-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B5B8F-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B5B90-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B5B91-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B5B8B-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B5BA3-363D-11E5-9242-09173F13E4C5 n4:271B5B89-363D-11E5-9242-09173F13E4C5 n4:271B5B8C-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B5B8A-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B5B99-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B5B9A-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B5B94-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B5B95-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B5B97-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B5B96-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B5B98-363D-11E5-9242-09173F13E4C5
n3:absorption
Approximately 75% absorbed from gastrointestinal tract
n3:affectedOrganism
Humans and other mammals
n3:caco2-Permeability
n4:271B5BA4-363D-11E5-9242-09173F13E4C5
n3:casRegistryNumber
5051-62-7
n3:category
n3:containedIn
n21:271B5B87-363D-11E5-9242-09173F13E4C5 n21:271B5B88-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B5B9E-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B5BA0-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B5BA1-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B5BA2-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B5B9D-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B5B9C-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B5B9F-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B5B8E-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5B9B-363D-11E5-9242-09173F13E4C5